| Added by | amaraver |
|---|---|
| Group name | EquipeAM |
| Item Type | Journal Article |
| Title | Circulating tumor DNA in advanced non-small-cell lung cancer patients with HIV is associated with shorter overall survival: Results from a Phase II trial (IFCT-1001 CHIVA) |
| Creator | Wislez et al. |
| Author | Marie Wislez |
| Author | Charlotte Domblides |
| Author | Laurent Greillier |
| Author | Julien Mazières |
| Author | Isabelle Monnet |
| Author | Lize Kiakouama-Maleka |
| Author | Xavier Quantin |
| Author | Jean Philippe Spano |
| Author | Charles Ricordel |
| Author | Philippe Fraisse |
| Author | Henri Janicot |
| Author | Clarisse Audigier-Valette |
| Author | Elodie Amour |
| Author | Alexandra Langlais |
| Author | Nathalie Rabbe |
| Author | Alain Makinson |
| Author | Jacques Cadranel |
| Author | Pierre Laurent-Puig |
| Author | Hélène Blons |
| Abstract | INTRODUCTION: HIV is an exclusion criterion for most lung cancer (LC) trials, however LC is the most common non-AIDS-defined malignancy in people living with HIV (PLHIV), poorer prognosis than the general population. Circulating tumor DNA (ctDNA) was a prognostic marker in LC patients from the general population. This study assessed ctDNA's prognostic value in PLHIV from a dedicated phase II trial. METHODS: Overall, 61 PLHIV with advanced non-squamous non-small-cell lung cancer (NSCLC) participated in the IFCT Phase II trial evaluating first-line four-cycle carboplatin (Ca) AUC5 pemetrexed (P) 500?mg/m2 induction therapy every 3 weeks, followed by P maintenance therapy. Blood samples collected before treatment were analyzed to detect ctDNA using ultra-deep targeted next-generation-sequencing (NGS). RESULTS: Appropriate samples were available from 55 PLVIH and analyzed for ctDNA detection. Including 42 males (76.4 %), 52.9 years median age, 51 smokers (92.7 %), five with non-squamous NSCLC Stage III (9%), 50 Stage IV (91 %), and performance status (PS) 0-2. ctDNA was detected in 35 patients (64 %), 22 with high and 13 with low ctDNA levels. Overall, 77 % were positive for TP53, 29 % for KRAS, and 11 % for STK11 mutations, more than one alteration was detected in 43 % of samples. Multivariate analysis showed that positive ctDNA was significantly associated with shorter PFS (HR, 4.31, 95 %CI: 2.06-8.99, p? |
| Publication | Lung Cancer (Amsterdam, Netherlands) |
| Volume | 157 |
| Pages | 124-130 |
| Date | 2021-07 |
| Journal Abbr | Lung Cancer |
| Language | eng |
| DOI | 10.1016/j.lungcan.2021.05.013 |
| ISSN | 1872-8332 |
| Short Title | Circulating tumor DNA in advanced non-small-cell lung cancer patients with HIV is associated with shorter overall survival |
| Library Catalog | PubMed |
| Extra | PMID: 34016488 |
| Tags | Biomarkers, Tumor, Carboplatin, Carcinoma, Non-Small-Cell Lung, clinic, HIV Infections, HIV positivity, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Pemetrexed |
| Date Added | 2022/08/31 - 14:26:00 |
| Date Modified | 2022/08/31 - 14:26:13 |
| Notes and Attachments | PubMed entry (Attachment) |
Institut de Recherche en Cancérologie de
